Business
Ocular Therapeutix™ Reports Third Quarter 2021 Financial Results and Business Update
DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg Recorded Net Quarterly Sales of $11.9 Million, Representing Year-Over-Year Growth of 120% FDA Approved
About this update from Ocular Therapeutix, Inc.
[{"type":"text","content":"\nDEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg Recorded Net Quarterly Sales of $11.9 Million, Representing Year-Over-Year Growth of 120%\n\nFDA Approved Supplemental New Drug Application (sNDA) for DEXTENZA for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis\n\nDEXTENZA Will Be Paid Through the End of 2022 and is Eligible for Separate Payment in the Ambulatory Surgery Center Beyond 2022\n\nConference Call to Discuss Third Quarter Results to be Held at 4:30 p.m. ET\n\n BEDFORD, Mass.--(BUSINESS WIRE)--\nOcular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the third quarter of 2021, and provided updates on its ophthalmology pipeline.\n\n“The previous four months have been an exceptionally busy time at Ocular,” said Antony Mattessich, President and Chief Executive Officer. “We had a couple of positive outcomes that we believe will set the course for the future of DEXTENZA®. The first was the approval of the sNDA for itching associated with allergic conjunctivitis that opens a large, new and discrete opportunity for DEXTENZA in the office setting. The second was Medicare’s final rule that determined that DEXTENZA will be paid separately in the hospital outpatient and ASC settings in 2022 and is eligible under the current criteria for separate payment in the ASC as a non-opioid pain management drug beyond 2022, positioning our vibrant business in the surgical setting to grow into the foreseeable future. We also continued to advance our pipeline. While we were disappointed with the outcome of our Phase 2 dry eye clinical trial with OTX-CSI, we expect to announce the Phase 2 clinical trial topline results for OTX-DED, our clinical trial in episodic dry eye disease in the first quarter of 2022. Further, our U.S.-based clinical trial of OTX-TKI in wet-AMD is enrolling well, and we expect to initiate a Phase 2 clinical trial for OTX-TIC in glaucoma by the end of the year. Overall, we are pleased with our continued progress as we enter a period of significant data and news flow that will shape our leadership position within ophthalmology.”\n\nRecent Business Updates\n\nFDA Approved Supplemental New Drug Application (sNDA) for DEXTENZA...